Magnesium supplementation in patients with hypertension.
European Society of Hypertension (ESH/ESC) and Polish Society of Hypertension (PTNT) guidelines do not recommend magnesium supplementation as an adjunctive therapy of patients with arterial hypertension. Nevertheless, Polish Institute of Food and Nutrition suggests increased supplementation of magnesium ions among hypertensive patients in everyday diet. The aim of the study was to assess a frequency of using magnesium supplements by hypertensive patients including demographic and clinical characteristics of the study group. From October 2015 to January 2016 data of 309 hypertensive patients from Outpatient Clinic were collected and analyzed. We assessed: demographic and medical therapy data, results of office blood pressure and heart rate measurements. We collected data of 309 patients aged between 19 and 84 (mean age 54.9±15.2 years) who were diagnosed with hypertension (HA). Mean time from diagnosis of HA was 12.8±9.9 years. The study group was represented in majority by subjects with secondary school level (40.8%) and university education (31.7%), retried (38.5%) or white-collars (26.9%). The proportion of patients using magnesium supplementation was 47.9% in the study group. Women more common than men were using magnesium supplements (68.2%, p=0.0001). Subjects preferred organic forms of magnesium supplements (85.1%) rather than inorganic (11.5%) or chelats (3.4%). There was no significant differences in SBP (142 vs 140 mmHg; p=0.93), DBP (80 vs 82 mmHg; p=0.42) and HR (71.5 vs 70.0 per min.; p=0.21) in group with and without magnesium supplementation. Pharmacological treatment and the proportion of patients that reach BP target (BP< 140/90 mmHg) were comparable in subgroup’s analysis. Nearly half of hypertensive patients, especially women, use magnesium supplements regularly. Organic forms are preferable. Supplemental doses of magnesium ions did not associate with SBP, DBP and HR values and reaching BP target in hypertensive patients.